最平飛機票 相關
廣告上個月有 超過 10 萬 名用戶曾瀏覽 hk.trip.com
我們的搜尋結果提供最新全球機票價格。 獲取實時航班狀態、飛行時間、出發及抵達時間。
Best Flight Deals? Take Big Discount Now. Don't miss. Airline Ticket. Cheapest Flight Deals? Last Minute Price Drops on Intl. & Domestic Airfare. Compare Today!
- Spring Sale: Up to 45% off One Way Flights
Unbeatable Cheap Rates. Save Up to 60% On Your Next Flight! Save Time & Money - Compare Cheap Flights and Save Today. Compare Now!
Get the Best Flight Deals for Your Next Destination with SmartFares. Com! Hurry, Call Now for SmartFares® Cheapest Airline Deals. Limited Deals to Book!
搜尋結果
Eisai expects the European Commission's decision for the MAA of lecanemab in the first quarter of FY2024 ending June 30, 2024, if the opinion from the CHMP is received by March 31, 2024, following discussion by the SAG.
2020年2月25日 · FUJI YAKUHIN will retain responsibility for manufacturing the formulation of dotinurad, and supply to Eisai. Eisai will be responsible for a New Drug Application for dotinurad in China and pay FUJI YAKUHIN upfront payment, development milestone and sales milestone.
2024年6月3日 · Eisai Announces Appointments of Directors and Corporate Officers. June 10, 2024. FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease. June 3, 2024. EISAI NAMED TO LIST OF THE TIME 100 MOST INFLUENTIAL COMPANIES.
2018年4月19日 · Eisai's news release World’s First Bile Acid Transporter Inhibitor “GOOFICE® 5mg Tablet” Launched in Japan is posted. Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate ...
Sayoko Sasaki. Inquiries: Vice President, Corporate Communications. Phone +81-3-3817-5120. Notice Concerning Appointment of New Representative Officer. Eisai Co., Ltd. (“the Company”) resolved at its Board of Directors meeting held on May 15, 2024, to appoint a new Representative Corporate Officer, effective June 14, 2024 as described below.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in ...
In May 2023, Eisai entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China, “BlissBio”), for BB-1701, a HER2-targeting antibody drug conjugate (ADC), with option rights for a strategic collaboration.
最平飛機票 相關
廣告上個月有 超過 10 萬 名用戶曾瀏覽 flightsearchdirect.com
Unbeatable rates across the world. Save Up to 60% on your next Flight! We search hundreds of agency and airline sites to find the best prices.
